New radioactive drug targets tough cancers in early trial

NCT ID NCT07006727

Recruiting now Disease control Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 29, 2026 · Updated 2 times

Summary

This early-phase study tests a new radioactive drug, 225Ac-ETN029, in 116 adults with advanced DLL3-positive cancers like small cell lung cancer or neuroendocrine tumors. The main goal is to check safety and find the right dose, while also seeing if the drug can shrink tumors. Participants must have tried at least one prior treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GASTROENTEROPANCREATIC NEUROENDOCRINE CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

digestive system neuroendocrine neoplasm neuroendocrine carcinoma prostate neuroendocrine neoplasm pulmonary large cell neuroendocrine carcinoma small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GASTROENTEROPANCREATIC NEUROENDOCRINE CARCINOMA LARGE CELL NEUROENDOCRINE CARCINOMA OF THE LUNG NEUROENDOCRINE PROSTATE CANCER SMALL CELL LUNG CARCINOMA

Contacts and locations

Locations

Corewell Health William Beaum Hosp
RECRUITING

Royal Oak, Michigan, 48073-6769, United States
Fred Hutchinson Cancer Research Center
RECRUITING

Seattle, Washington, 98109-1024, United States
Massachusetts General Hospital
RECRUITING

Boston, Massachusetts, 02114, United States
Novartis Investigative Site
RECRUITING

Montreal, Quebec, H3T 1E2, Canada
Novartis Investigative Site
RECRUITING

Seoul, Seoul, 03080, South Korea
Novartis Investigative Site
RECRUITING

Seoul, 03722, South Korea
University Of Iowa
RECRUITING

Iowa City, Iowa, 52242, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.